Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease-Reference-Cited by-同舟云学术

Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease

Published:2020-11-24 Issue:2 Volume:11 Page:308-325
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Catenacci Daniel V.T.,Moya Stephanie,Lomnicki Samantha,Chase Leah M.,Peterson Bryan F.,Reizine Natalie,Alpert Lindsay,Setia Namrata,Xiao Shu-Yuan,Hart John,Siddiqui Uzma D.,Hogarth D. Kyle^ORCID,Eng Oliver S.^ORCID,Turaga Kiran,Roggin Kevin,Posner Mitchell C.,Chang Paul^ORCID,Narula Sunil,Rampurwala Murtuza,Ji Yuan^ORCID,Karrison Theodore,Liao Chih-Yi,Polite Blase N.,Kindler Hedy L.

Funder

NIH

University of Chicago Comprehensive Cancer Center

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant Immunotherapy in Gastroesophageal Cancer: A Promising Early Signal?;Journal of Clinical Oncology;2024-02-01

2. Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study;Journal of Clinical Oncology;2024-01-20

3. A Practical Approach to Interpreting Circulating Tumor DNA in the Management of Gastrointestinal Cancers;Clinical Chemistry;2024-01

4. Assessment of the impact of FcγRIIIA single-nucleotide polymorphisms on the efficacy of IgG1 monoclonal antibodies in patients with advanced gastroesophageal adenocarcinoma;ESMO Gastrointestinal Oncology;2023-12

5. Clinical Implication of Concurrent Amplification of MET and FGFR2 in Metastatic Gastric Cancer;Biomedicines;2023-11-28